Comparisons of the MxA biomarker—assessed by MxA-EIA and MxA-FACS—with clinical and laboratory parameters of pSS patients
| Variable | MxA-EIA | MxA-Facs | ||||
|---|---|---|---|---|---|---|
| N | r | p Value | N | r | p Value | |
| ESSDAI score | 24 | 0.65 | <0.01 | 28 | 0.45 | 0.02 |
| Laboratory parameters | ||||||
| Rf (IE/ml) | 22 | 0.57 | 0.01 | 26 | 0.33 | n.s. |
| C3 (g/l)* | 27 | 0.03 | n.s. | 33 | −0.17 | n.s. |
| C4 (g/l) | 27 | −0.07 | n.s. | 33 | −0.43 | n.s. |
| IgG (g/l)* | 29 | 0.52 | <0.01 | 35 | 0.40 | 0.02 |
| IgA (g/l) | 27 | 0.44 | 0.02 | 33 | 0.41 | 0.02 |
| IgM (g/l) | 27 | 0.46 | 0.02 | 33 | 0.18 | n.s. |
| CRP (mg/l) | 26 | 0.09 | n.s. | 31 | 0.22 | n.s. |
| Hb (mmol/l) | 29 | −0.45 | 0.02 | 35 | −0.61 | n.s. |
| Thrombocytes (*10E9/l)* | 28 | 0.20 | n.s. | 34 | 0.03 | n.s. |
| Lymphocytes (*10E9/l)* | 26 | 0.03 | n.s. | 32 | −0.11 | n.s. |
| Neutrophils (*10E9/l) | 26 | −0.40 | 0.05 | 32 | −0.18 | n.s. |
| Variable | N (%) | Z | p Value | N (%) | Z | p Value |
|---|---|---|---|---|---|---|
| Autoantibodies | ||||||
| Anti-SSA | 24/29 (83) | −3.07 | <0.01 | 30/35 (86) | −2.40 | 0.02 |
| Anti-Ro52 | 16/22 (73) | −2.26 | 0.02 | 21/27 (78) | −1.98 | 0.05 |
| Anti-Ro60 | 15/22 (68) | −3.02 | <0.01 | 19/27 (70) | −2.76 | 0.01 |
| Anti-SSB | 19/29 (66) | −3.20 | <0.01 | 23/35 (66) | −1.63 | n.s. |
| Medical therapy | ||||||
| Pilocarpine | 7/29 (24) | −1.36 | n.s. | 9/35 (26) | −1.47 | n.s. |
| Plaquenil | 23/29 (79) | −2.05 | 0.04 | 26/35 (74) | −3.25 | <0.01 |
| Corticosteroids | 2/29 (7) | −1.64 | n.s. | 3/35 (9) | −0.59 | n.s. |
Data are presented as Spearman's rho (r) or according to κ2 test (Z), unless otherwise mentioned.
*Data normally distributed are presented as Pearson's rho (r).
CRP, C-reactive protein; Hb, haemoglobin; n.s., not significant; Rf, rheumatoid factor.